pepdex
← Back to index
048

DNSP-11

11-amino-acid peptide derived from the prohormone region of preprodopamine (pro-PRO-D peptide). Pre-clinical neuroprotection for dopaminergic neurons in Parkinson's models.

Nootropic
Evidence: Anecdotal
Half-life
Short (minutes)
Route
Subcutaneous (intra-cranial in animal models)
Cycle
Pre-clinical
Schedule
Daily in animal protocols
In plain English

DNSP-11 is a tiny peptide derived from the precursor of dopamine. It protects dopaminergic neurons in Parkinson's animal models. Pre-clinical research only — there is no human protocol, and dosing community vendors sell does not match clinical trial material.

Status & legality
Natty?
Not natty
FDA
Not approved

Not FDA approved. Pre-clinical.

Compounding
Not classified

Not formally categorized in the FDA bulks lists.

WADA
Not listed
Prescribed

Not prescribed in conventional medicine.

Who it's for

  • Researchers studying Parkinson's disease pathways
  • Neurodegeneration research contexts
  • Educational reference — limited human data

What to expect

  1. Week 1

    Subtle. No published human user-reports of acute effect.

  2. Week 4

    Animal-model neuroprotection markers shift here.

  3. Week 8

    No long-term human data exists.

How it works (mechanism)

11-amino-acid peptide derived from the prohormone region of preprodopamine. Pre-clinical neuroprotection via mechanisms that may include direct neurotrophic action on dopaminergic neurons.

Dosing protocol

No standardized human protocol. Animal-model dosing varies. Community use is highly experimental.

Stacks well with

Standalone — too experimental to stack

Side effects

01Limited human safety data
02Theoretical effects on dopaminergic signaling
03Injection-site irritation

When NOT to use

  • Active psychiatric medication regimen affecting dopamine
  • Pregnancy / nursing
  • Anyone risk-averse to pre-clinical compounds

Common mistakes

  • Treating it as Parkinson's treatment (it's pre-clinical research)
  • Stacking it with dopamine agonists
  • Long cycles without safety data

Educational only. User-specific dosing is between you and a qualified provider.

Frequently asked

What is DNSP-11?+
DNSP-11 is a tiny peptide derived from the precursor of dopamine. It protects dopaminergic neurons in Parkinson's animal models. Pre-clinical research only — there is no human protocol, and dosing community vendors sell does not match clinical trial material.
Is DNSP-11 FDA approved?+
Not FDA approved. Pre-clinical.
Is DNSP-11 banned by WADA?+
DNSP-11 is not currently on the WADA prohibited list.
Are you still natty after taking DNSP-11?+
No. DNSP-11 is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe DNSP-11?+
Not prescribed in conventional medicine.
What's the typical dose of DNSP-11?+
No standardized human protocol. Animal-model dosing varies. Community use is highly experimental.
What are the side effects of DNSP-11?+
Common side effects include: Limited human safety data; Theoretical effects on dopaminergic signaling; Injection-site irritation. Less common effects and full safety details are on the entry page.
How long until DNSP-11 starts working?+
Subtle. No published human user-reports of acute effect.